Nypozi™ (filgrastim-txid) – New biosimilar approval
June 28, 2024 - The FDA approved Tanvex’s Nypozi (filgrastim-txid), biosimilar to Amgen’s Neupogen (filgrastim).
June 28, 2024 - The FDA approved Tanvex’s Nypozi (filgrastim-txid), biosimilar to Amgen’s Neupogen (filgrastim).